Alvotech reported a second-quarter loss of $0.05 per share, $0.02 wider than the analyst consensus of a $0.04 loss, as revenue totaled $106 million against an estimated $111.5 million.
The company’s results fell short of market expectations despite a 19.46% gain over the prior three months. Shares closed at $3.99 on Wednesday, though the stock remains down 52.89% over the past 12 months.
Alvotech’s quarterly performance included no upward EPS revisions in the last 90 days, with a single negative revision recorded during the period. The company’s financial health score was rated as "good performance" by InvestingPro.
The biotech firm’s earnings miss follows a challenging year for the sector, with broader market conditions pressuring valuations amid rising interest rates and regulatory scrutiny.
